65,437 trials
Healthy Volunteers (Meningococcal Infection)
Primary: Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination…
Lymphoid Leukemia · Myeloid Leukemia · Monocytic Leukemia
Primary: The Proportion of Patients That Experience Non-relapse Mortality (NRM) — 5 Participants
Acute Myeloid Leukemia · Myeloid and Monocytic Leukemia · Myelodysplastic Syndromes
Primary: Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS) — 36 Percentage of…
Esophageal Squamous Cell Carcinoma (ESCC)
Primary: Overall Survival (OS) — 17.2; 10.6 months — p=<0.0001
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Type 2 Diabetic Patients
Primary: Change in Post-ischemic Forearm Blood Flow — 3.60; 1.00 ml/100ml — p=0.004
Wilson Disease
Primary: Area Under The Plasma Concentration Versus Time Curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) Of Plasma Total Molybdenum After Each Dose…
Platelet Dysfunction
Primary: Platelet Reactions Units Pre-DAPA Tx and Post-DAPA Tx — 160.93 PRU
Childhood Cataract
Primary: Results of Red-reflex and Infrared-reflex Tests Compared to Gold Standard — 17; 54; 32; 7 eyes
Metastatic Hormone-Sensitive Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as…
Liposarcoma · Osteogenic Sarcoma · Ewing/Ewing-like Sarcoma
Primary: Progression-free Survival (PFS). Cohort A and Cohort B — 1.87; 2.07; 3.6; 1.7 months
Constipation
Primary: % of Subjects With Treatment Response — 42; 34; 30; 20 Participants — p=0.034
Primary Immune Deficiency Disorder
Primary: IgG Trough Levels From Baseline to End of Study (28 Weeks) — 0.144; 0.065; -0.593 g/L
Diabetes Mellitus, Type 2
Primary: Glycemic Control — -.46; -.93; -.46; -.23 change in units of percents — p=.214
Multiple Myeloma
Primary: Number of Participants With MRD Negativity by the Completion of 6 Months of Daratumumab Therapy — 6; 4 Participants